Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a ...

Arbutus Biopharma (ABUS) is a clinical-stage biotech focused on LNP technology, with value now hinging on ongoing patent litigation against Moderna and Pfizer/BioNTech. Recent management changes and ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest update is out from Arbutus ...

WARMINSTER, Pa. (AP) — WARMINSTER, Pa. (AP) — Arbutus Biopharma Corp. (ABUS) on Wednesday reported second-quarter net income of $2.5 million, after reporting a loss in the same period a year earlier.

“We delivered a strong quarter, marked by positive quarterly earnings resulting from the conclusion of our Greater China partnership with Qilu,” said Lindsay Androski, President and CEO of Arbutus.

To enquire about specific property features for 78A Arbutus Street, Canley Heights, contact the agent. What is the size of the property at 78A Arbutus Street, Canley Heights? The external land size ...

WARMINSTER, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The end of the deal, which ...

Major health care provider, Kaiser Permanente, is expanding its reach on the Central Coast. In January, they opened a new facility in Salinas and now it's setting its sights on Marina near Second ...

A lot has happened since I last put Arbutus Biopharma Corporation (NASDAQ:ABUS) in the spotlight early last summer. This clinical stage biopharma concern. Arbutus laid off approximately 40% of its ...

Arbutus Biopharma is stripping back its workforce to just a “core team” needed to oversee mid-stage trials of the biotech's potential functional cure for hepatitis B. Lindsay Androski, who joined ...